Want to know if this job is worth applying to?
San Diego, California, United States
Onsite
Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
ESSENTIAL JOB FUNCTIONS:
Join us as we embark on an exciting journey in transforming the treatment landscape of acute myeloid leukemia (AML). We are seeking a dynamic and experienced Marketing Director, Peer to Peer Strategy to lead the development and execution of thought leader engagement strategies supporting KOMZIFTI® (ziftomenib) in relapsed/refractory (R/R) NPM1-mutant AML.
Reporting to the Senior Director of Brand Strategy and Marketing, this individual will serve as the strategic architect behind Opinion Leader (OL) engagement, advocacy development, insight generation, advisory board strategy, speaker bureau, and congress strategy. This role will be responsible for transforming field-based observations into actionable business recommendations that influence brand strategy and commercial execution.
Working in close partnership with Regional Marketing, Brand Marketing, Medical Affairs, Market Access, Sales Leadership, and Compliance, this individual will identify emerging trends, prioritize engagement opportunities, shape advocacy development plans and identify insights to improve outcomes for patients with NPM1-m AML.
The successful candidate will bring deep oncology marketing experience, strong OL engagement expertise, and a demonstrated ability to translate strategic insights into impactful educational and engagement programs.
Responsibilities
OL Engagement Strategy
OL Mapping
Advocacy Development
Insight Generation & Strategic Interpretation
Speaker Bureau & Peer-to-Peer Education
Advisory Boards & Customer Insights
Congress Strategy & Execution
Ensure all above activities are conducted in compliance with company policies and regulatory requirements.
The preceding job description has been designed to indicate the general nature and level of work performed by employees within this classification. It is not designed to contain or be interpreted as a comprehensive inventory of all duties, responsibilities and qualifications required of employees assigned to the job.
JOB SPECIFICATIONS:
Required Qualifications
Preferred Qualifications
The base range for this role is $234,000 - $262,000. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
#LI-RM1
Kura’s Values that are used for candidate selection and performance assessments:
The Kura Package
Kura Oncology is a commercial-stage biopharmaceutical company committed to discovering and developing innovative precision medicines to help patients with cancer lead better, longer lives.
Through our deep understanding of cancer biology and decades of experience in precision oncology, we are studying the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, with the goal of improving long-term clinical benefit.
Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
If you are a California resident, please see the attached Privacy Notice CA Privacy Notice